Y-mAbs Therapeutics, Inc. YMAB
8.61 0.00 (+0.00%)
At closeSep 16, 2025, 4:00 PM EDT
8.61 Day range 8.61
6.48 52-week range 20.90
Analyst view
Consensus: buy
Buy
Price target (mean) 20.64 +139.7% upside
Now 8.61
- Target (low)
- 11.00
- Target (mean)
- 20.64
- Target (high)
- 26.00
Ratings (0m) 11 9 buy · 1 hold · 1 sell
- Strong buy2
- Buy7
- Hold1
- Sell1
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 10
- 2 months ago 9
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.1225 | -0.25 – 0.05 | -0.02 | -512.5% | 26.99M | +15.5% | 10 |
| Next quarter | -0.14667 | -0.22 – -0.04 | -0.15 | +2.2% | 24.37M | +22.3% | 5 |
| Current year | -0.57625 | -0.83 – -0.21 | -0.49 | -17.6% | 88.53M | +4.4% | 10 |
| Next year | -0.46875 | -0.95 – -0.15 | -0.57625 | +18.7% | 106.84M | +20.7% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 5, 2024 | Brookline Capital | Initiated | — | Buy |
| Nov 18, 2024 | Oppenheimer | Initiated | — | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 10, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 16, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 13, 2024 | Morgan Stanley | Maintained | Underweight | Underweight |
| Aug 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 13, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 11, 2024 | Jones Trading | Initiated | — | Buy |
| Jun 28, 2024 | Truist Securities | Initiated | — | Buy |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 4, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 4, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Feb 20, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 22, 2023 | JP Morgan | Maintained | Underweight | Underweight |
| Aug 14, 2023 | Morgan Stanley | Maintained | Underweight | Underweight |
| Aug 14, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 25, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 7, 2023 | Canaccord Genuity | Reiterated | Buy | Buy |
| May 15, 2023 | B of A Securities | Maintained | Neutral | Neutral |
| May 10, 2023 | Morgan Stanley | Maintained | — | Underweight |
| May 10, 2023 | Wedbush | Upgrade | Neutral | Outperform |
| May 9, 2023 | Canaccord Genuity | Maintained | — | Buy |
| Apr 4, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 3, 2023 | Guggenheim | Downgrade | Buy | Neutral |